Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Tashi, T., Hermine, O., Castells, M., Guilarte, M., Sabato, V., Maurer, M., Panse, J., Alvarez-Twose, I., Cabral, R., Bird, R., Barete, S., Bouillet, L., Hermans, M., Van Daele, P., González-De-Olano, D., Griffiths, E. A., Jurcic, J., Dybedal, I., Damaj, G. L., … Livideanu, C. B. (2023). Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial. Blood, 142(Supplement 1), 76–76. https://doi.org/10.1182/blood-2023-188904
Authors:
Tsewang Tashi
Olivier Hermine
Mariana Castells
Mar Guilarte
Vito Sabato
Marcus Maurer
Jens Panse
Iván Álvarez‐Twöse
Renata Cabral
Robert Bird
Stéphane Barète
Laurence Bouillet
Maud A.W. Hermans
Paul Van Daele
David González‐de‐Olano
Elizabeth A. Griffiths
Joseph G. Jurcic
Ingunn Dybedal
Gandhi Damaj
Philippe Schafhausen
Chiara Elena
Tse‐Chieh Teh
Pankit Vachhani
Caroline Labe
Saranya Venugopal
Kevin He
Javier I. Muñoz‐González
Ben Lampson
Robyn M. Scherber
Prithviraj Bose
Clive Grattan
Thanai Pongdee
Tracy I. George
C. Bulaï Livideanu
Affiliated Authors:
Joseph G. Jurcic
Columbia Affiliation:
Subjects:
Role of Mast Cells in Immunoregulation and Disease (OpenAlex Topic)
Hypereosinophilic Syndrome and Related Disorders (OpenAlex Topic)
Hypersensitivity Reactions to Drugs and Medications (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2023-188904
DOI:
10.1182/blood-2023-188904
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: